FindTrial
Sign In

Estimated effect-site concentration (EC95) of remifentanil for i-gel insertion without neuromuscular blockade during remimazolam induction

Estimated effect-site concentration (EC95) of remifentanil for i-gel insertion without neuromuscular blockade during remimazolam induction

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CRIS
Registry ID
KCT0006968
Enrollment
40
Registered
2022-01-27
Start date
2022-02-07
Completion date
Unknown
Last updated
2022-09-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

Gachon University Gil Medical Center
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: ? Ages 19-65 ? ASA 1, 2 ? Those who are scheduled for surgery using i-gel LMA as an airway maintainer under general anesthesia

Exclusion criteria

Exclusion criteria: ? Those who are allergic to drugs used during the study ? Research subjects with high risk of aspiration - hiatus hernia, gastro-esophageal reflux disease, non-fasting status ? When endotracheal intubation is expected to be difficult - Restriction of mouth opening, restriction of cervical extension, Mallampati class IV ? Severe obesity (BMI>35 kg/m2)

Design outcomes

Primary

MeasureTime frame
EC95 of remifentanil—

Countries

Korea, Republic of

Contacts

Public Contactjungju choi

Gachon University Gil Medical Center

jjchoi2@gilhospital.com+82-32-460-3624

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026